Showing results (131-140 of 223) with videos related to
Sort By:
Pageof 23
European Journal of Cancer (Oxford, England : 1990)|July 1, 2022
Evaluation of pembrolizumab monotherapy in patients with previously treated advanced salivary gland carcinoma in the phase 2 KEYNOTE-158 studyCaroline Even, Jean-Pierre Delord, Katharine A Price, et al.Frontiers in Immunology|August 13, 2024
Ceramide metabolism alterations contribute to Tumor Necrosis Factor-induced melanoma dedifferentiation and predict resistance to immune checkpoint inhibitors in advanced melanoma patientsCarine Dufau, Matthieu Genais, Elodie Mucher, et al.JHEP Reports : Innovation in Hepatology|April 15, 2024
A phase Ib/II trial of capmatinib plus spartalizumab <i>vs.</i> spartalizumab alone in patients with pretreated hepatocellular carcinomaArmando Santoro, Eric Assenat, Thomas Yau, et al.Clinical Chemistry|August 8, 2019
Circulating Tumor Cells as a Prognostic Factor in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: The CIRCUTEC Prospective StudyRenaud Garrel, Martine Mazel, Françoise Perriard, et al.Journal of Molecular Cell Biology|September 11, 2019
Tumor cells educate mesenchymal stromal cells to release chemoprotective and immunomodulatory factorsAugustin Le Naour, Mélissa Prat, Benoît Thibault, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 26, 2021
Regorafenib-Avelumab Combination in Patients with Microsatellite Stable Colorectal Cancer (REGOMUNE): A Single-arm, Open-label, Phase II TrialSophie Cousin, Coralie Cantarel, Jean-Philippe Guegan, et al.Oncotarget|April 29, 2015
Dual targeting of HER1/EGFR and HER2 with cetuximab and trastuzumab in patients with metastatic pancreatic cancer after gemcitabine failure: results of the "THERAPY"phase 1-2 trialEric Assenat, David Azria, Caroline Mollevi, et al.BMJ Oncology|February 25, 2026
First-in-human phase 1 dose-escalation study of W0180, an anti-VISTA monoclonal antibody, with and without pembrolizumab in patients with locally advanced or metastatic solid tumoursCarlos Gomez-Roca, Stéphane Champiat, Francois-Xavier Danlos, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 13, 2015
CD44 Isoform Status Predicts Response to Treatment with Anti-CD44 Antibody in Cancer PatientsFabian Birzele, Edgar Voss, Adam Nopora, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 4, 2020
Combining Nivolumab and Ipilimumab with Infliximab or Certolizumab in Patients with Advanced Melanoma: First Results of a Phase Ib Clinical TrialAnne Montfort, Thomas Filleron, Mathieu Virazels, et al.Pageof 23